ABSTRACT
The role that genetics plays in the development of late-onset Alzheimer’s disease (AD) has been widely studied, with one study estimating genetics to account for more than 50% of the phenotypic variance. This chapter reviews examples of a universal “one-size-fits-all” prevention strategy without any distinction that is based on genetics or other personalized risk factors versus a clinical precision medicine approach. Randomized studies in AD prevention have traditionally used either single or multiple interventions to determine efficacy across a host of clinical outcome measures. A precision medicine approach to AD prevention will need to fully utilize the genome in order to make personalized recommendations. The chapter discusses some of the genetic influencers on late-onset AD that can be ordered by a practicing physician and provides examples of a targeted precision medicine approach based on these genetic factors. The genomic-centered foundation that forms the core of precision medicine reduces diseases to their molecular and cellular processes.
